BrainEver is a biotechnology company, with a focus on discovering and developing First-in-class therapies for the treatment of neurodegenerative diseases.

Our Platform

BrainEver platform is based on the translation of the work by Alain Prochiantz and colleagues on brain development and physiology. They demonstrated that homeoproteins, first identified as early developmental regulators, are also active throughout life, when they participate in the maintenance and protection of several neuronal populations. Homeoproteins control several neuronal functions, including epigenetic stability and metabolism.

The first project, BREN01, is Engrailed 1 for the treatment of Parkinson’s disease.

Homeoproteins are being explored to treat other neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Huntington disease and some optic neuropathies.


BrainEver S.A.S

General Information:


74 rue du Faubourg Saint-Antoine 75012 Paris, France

Additional information:

RCS: 810 542 506 Paris – SIRET: 810 542 506 000 11

Registered capital: 38 500,00 €

Terms of Use Ι Privacy Policy Ι Cookies

© 2020 BrainEver. All rights reserved.